Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2017

View Archived Issues

Celleron Therapeutics announces completion of a new funding round with international investors

Imara's IMR-687 awarded FDA orphan drug designation for SCD

Shionogi reflects on accomplishments of third quarter of fiscal 2016

Roche updates pipeline events of fourth quarter 2016

Takeda Pharmaceutical reports highlights of third quarter of fiscal 2016

Combination of NDM-1 PPMO and meropenem shows therapeutic potential in vitro and in vivo

Malin acquires stake in Artizan Biosciences

HOTAIR expression as a potential new independent prognostic biomarker in endometrial cancer

Novel KDF1 gene variant in a multigenerational family with ectodermal dysplasia

AXT-107 suppresses ocular neovascularization and vascular leakage in vivo

Kiadis updates development status of ATIR-101 and ATIR-201

University of Maryland describes novel Mcl-1 inhibitors

EffiKIR trial of lirilumab in elderly patients with AML does not meet primary efficacy endpoint

Medicines for Malaria Venture, University of Cape Town divulge PI4Kbeta inhibitors

Array BioPharma identifies novel RET kinase inhibitors

Enanta Pharmaceuticals discovers hepatitis B antiviral agents

Sichuan Haisco patents muscarinic M3 receptor antagonists/beta2-adrenoceptor agonists

Axovant Sciences enters debt financing agreement

Ablynx submits European MAA for caplacizumab to treat acquired TTP

FDA approves Seeker System to screen for four lysosomal storage disorders in newborns

FDA issues complete response letter for CL-108 NDA

Seikagaku initiates phase III study of SI-613 to treat osteoarthritis in Japan

Canadian pilot project to accelerate precision medicine

Bionomics earns milestone from Merck & Co. for phase I study of Alzheimer's candidate

Ergomed reports topline results from phase II trial of lorediplon for insomnia

Amryt reports encouraging preclinical results for AP-102

FDA accepts for review sBLAs for Merck & Co.'s Keytruda

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...